ArticleNeoplasia (New York, N.Y.)2007
Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers.
Article in Neoplasia (New York, N.Y.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- DYRK kinases phosphorylate IL-17RA at S801.Serican journal of medicine · 2026Article
- Prolonged neoadjuvant hormonal therapy enhances IL-17 A/STAT3-mediated inflammation in prostate cancer.Discover oncology · 2025Article
- The Role of Immunohistochemistry for AMACR/p504s and p63 in Distinguishing Prostate Cancer from Benign Prostate Tissue Samples in Botswana.Research and reports in urology · 2025Article
- Altered expression pattern of immune response-related genes and isoforms in hypersensitivity pneumonitis lung fibroblasts.Scientific reports · 2024Article
- Identification of ferroptosis related genes and pathways in prostate cancer cells under erastin exposure.BMC urology · 2024Article
- SCFBiomedicines · 2024Article
- The role of interleukin-17 in inflammation-related cancers.Frontiers in immunology · 2024Review
- Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives.Biomedicines · 2023Review
- Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options.Journal of immunology research · 2020Article
- Interleukin-17 Promotes Migration and Invasion of Human Cancer Cells Through Upregulation of MTA1 Expression.Frontiers in oncology · 2019Article
- Article
- Follistatin-like protein 1 modulates IL-17 signaling via IL-17RC regulation in stromal cells.Immunology and cell biology · 2017Article
- Anti-Inflammatory Effect of Dialyzable Leukocyte Extract in Autoimmune Prostatitis: Evaluation in Animal Model.BioMed research international · 2017Article
- Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.International journal of molecular sciences · 2016Review
- Article
- Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.The Prostate · 2014Article
- Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis.Drug design, development and therapy · 2013Article
- Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2012Article
- Interleukin-17 Induces Expression of Chemokines and Cytokines in Prostatic Epithelial Cells but Does Not Stimulate Cell Growth In Vitro.International journal of medical and biological frontiers · 2012Article
- The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases.Immunology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-17RC (interleukin-17 receptor-like) gene codes for a transmembrane protein, the full length of which inhibits apoptosis in prostate cancer cells. IL-17RC gene transcribes over a dozen different splice variants of mRNA. However, it is not known whether there are relevant protein isoforms. Here we report that different IL-17RC protein isoforms were detected by two different antibodies. The isoform as detected byanti-IL-17RC intracellular domain antibodies (anti-ICD) was expressed at higher levels in androgen-independent prostate cancer cell lines (PC3 and DU145) than in androgen-dependent prostatic cell lines (RWPE-1, pRNS-1-1, MLC-SV40, and LNCaP). In contrast, several isoforms as detected by anti-IL-17RC extracellular domain antibodies (anti-ECD) were expressed at significantly higher levels in androgen-dependent prostatic cell lines than in androgen-independent ones. Furthermore, immunohistochemical staining of prostate tissue microarrays showed that IL-17RC protein expression was significantly higher in androgen-independent prostate cancers than in androgen-dependent ones when anti-ICD was used, whereas the trend was reversed using anti-ECD. These observations provide evidence that IL-17RC protein isoforms are differentially expressed in prostatic cells and cancer tissues and may play a negative or positive role in the initiation and progression of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.